255 related articles for article (PubMed ID: 28860002)
1. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.
Bohl SR; Kuchenbauer F; von Harsdorf S; Kloevekorn N; Schönsteiner SS; Rouhi A; Schwarzwälder P; Döhner H; Bunjes D; Bommer M
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2172-2177. PubMed ID: 28860002
[TBL] [Abstract][Full Text] [Related]
2. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
4. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM; Efebera Y; Jaglowski S; Penza S; Cohen D; Devine S; Cataland S
Bone Marrow Transplant; 2016 Sep; 51(9):1241-4. PubMed ID: 27064689
[No Abstract] [Full Text] [Related]
7. Eculizumab in Transplant-Associated Thrombotic Microangiopathy.
Dhakal P; Giri S; Pathak R; Bhatt VR
Clin Appl Thromb Hemost; 2017 Mar; 23(2):175-180. PubMed ID: 26259912
[TBL] [Abstract][Full Text] [Related]
8. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
Jan AS; Hosing C; Aung F; Yeh J
Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
[TBL] [Abstract][Full Text] [Related]
9. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
11. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
13. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
14. Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: A case report.
Kitamura F; Yamaguchi M; Nishimura M; Katsuno T; Ito M; Sugiyama H; Iwagaitsu S; Nobata H; Kinashi H; Ishimoto T; Banno S; Ito Y
Mod Rheumatol Case Rep; 2022 Jun; 6(2):254-259. PubMed ID: 35425980
[TBL] [Abstract][Full Text] [Related]
15. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
[TBL] [Abstract][Full Text] [Related]
16. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
18. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
19. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
[TBL] [Abstract][Full Text] [Related]
20. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
